MARKET

IDYA

IDYA

Ideaya Biosciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.88
+0.06
+0.43%
After Hours: 13.88 0 0.00% 17:00 06/24 EDT
OPEN
14.07
PREV CLOSE
13.82
HIGH
14.17
LOW
13.27
VOLUME
824.82K
TURNOVER
0
52 WEEK HIGH
28.00
52 WEEK LOW
8.14
MARKET CAP
536.32M
P/E (TTM)
-9.4070
1D
5D
1M
3M
1Y
5Y
IDEAYA Biosciences to Present at the 2022 Jefferies Global Healthcare Conference
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 2022 Jefferies Global Healthcare Conference.
PR Newswire · 06/08 10:00
Ideaya Biosciences price target raised to new Street high at Roth; sees 341% upside
Roth Capital Partners is raising its price target on Ideaya Biosciences (NASDAQ:IDYA) to a Street high of $46 from $42 (341% upside based on Monday's close) while maintaining a buy
Seekingalpha · 05/17 14:19
Recap: IDEAYA Biosciences Q1 Earnings
  IDEAYA Biosciences (NASDAQ:IDYA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/10 12:47
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Tops Revenue Estimates
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 12.20% and 33.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 11:15
IDEAYA Biosciences GAAP EPS of -$0.36 beats by $0.06, revenue of $11.36M beats by $5.03M
IDEAYA Biosciences press release (NASDAQ:IDYA): Q1 GAAP EPS of -$0.36 beats by $0.06. Revenue of $11.36M (+57.8% Y/Y) beats by $5.03M. Strong balance sheet of ~$346 million cash, cash equivalents
Seekingalpha · 05/10 10:26
-- Earnings Flash (IDYA) IDEAYA BIOSCIENCES Reports Q1 Revenue $11.4M
MT Newswires · 05/10 06:03
We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 05/06 13:59
IDEAYA Biosciences to Participate in Investor Conferences in May 2022
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in May 2022.
PR Newswire · 05/03 10:00
More
No Data
Learn about the latest financial forecast of IDYA. Analyze the recent business situations of Ideaya Biosciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

75.00%Strong Buy
25.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IDYA stock price target is 25.43 with a high estimate of 34.00 and a low estimate of 16.00.
High34.00
Average25.43
Low16.00
Current 13.88
EPS
Actual
Estimate
-0.40-0.30-0.20-0.10
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 121
Institutional Holdings: 34.54M
% Owned: 89.40%
Shares Outstanding: 38.64M
TypeInstitutionsShares
Increased
43
3.48M
New
11
2.65M
Decreased
31
1.79M
Sold Out
19
4.00M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Non-Executive Chairman/Independent Director
Timothy Shannon
President/Chief Executive Officer/Director
Yujiro Hata
Chief Financial Officer/Senior Vice President/IR Contact Officer
Paul Stone
Senior Vice President/Chief Scientific Officer
Michael White
Senior Vice President/General Counsel/Secretary
Jason Throne
Vice President
Matthew Maurer
Independent Director
M. Garret Hampton
Independent Director
Susan Kelley
Independent Director
Catherine Mackey
Independent Director
Scott Morrison
Independent Director
Terry Rosen
Independent Director
Jeffrey Stein
Independent Director
Wendy Yarno
No Data
No Data
About IDYA
IDEAYA Biosciences, Inc. is a synthetic lethality-focused precision medicine oncology company. The Company is focused on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead synthetic lethality product candidate, IDE397, is a clinical-stage methionine adenosyltransferase 2a (MAT2A) inhibitor for patients with solid tumors having methylthioadenosine phosphorylase (MTAP) deletions. Its clinical-stage product candidate, darovasertib (IDE196), is a protein kinase C (PKC), inhibitor that is being evaluated as a synthetic lethal combination therapy in patients having genetically defined cancers having GNAQ or GNA11 gene mutations. Its pipeline also includes preclinical research programs directed to synthetic lethality targets PARG, Pol Theta, Werner Helicase, and certain deoxyribonucleic acid (DNA) damage targets. The PARG program is for patients having tumors with a defined biomarker based on genetic mutations.

Webull offers kinds of Ideaya Biosciences Inc stock information, including NASDAQ:IDYA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDYA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IDYA stock methods without spending real money on the virtual paper trading platform.